Provider fact sheet · dataset v2026.08.14-4 · last touched 2026-08-14
NovoCare: GLP-1 programs, prices, and verification status (2026)
NovoCare lists from $149/month (reported). Novo Nordisk's direct channel: oral Wegovy 25 mg at ~$149/month since the December 2025 launch (fasting rules apply — it's the SNAC formulation) and Wegovy injection self-pay programs.
Programs and pricing, in plain sentences
Oral Wegovy 25 mg (semaglutide) (oral tablet (peptide + SNAC)) is advertised at $149/month — status: reported. Key fields: no membership fee; no commitment required; flat across doses (claimed); 12-month total $1,788. Launched Dec 2025; fasting rules apply (SNAC formulation).
Every figure above carries its status — operator claims come from the provider, reported from third parties we cite, verified only after our own checkout walk. Machine-readable version: providers.json.
Verification status and open items
Current status: reported, last touched 2026-08-14. No open structural items; pricing re-verification is on the monthly cycle. Source on file: www.kff.org. Corrections land within 48 hours via the public log — if your checkout contradicts this page, that report changes the dataset.
How NovoCare fits the market
Novo Nordisk's direct channel: oral Wegovy 25 mg at ~$149/month since the December 2025 launch (fasting rules apply — it's the SNAC formulation) and Wegovy injection self-pay programs. For semaglutide-first cash payers who want the approved product, this is the ceiling to beat. Where it lands overall: the price ladder, the category winners, and the program finder all compute from the same dataset this page renders.
Advertising disclosure: outbound provider links may be commission-bearing; our partner relationship with NexLife is disclosed on the ownership page and never alters statuses or rankings.